Sommadossi Jean-Pierre 4

4 · Atea Pharmaceuticals, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Atea (AVIR) CEO Jean‑Pierre Sommadossi Exercises Options, Sells Shares

What Happened

Jean‑Pierre Sommadossi, President, CEO and Chairman of Atea Pharmaceuticals (AVIR), had equity awards convert and exercised options. On Jan 31, 2026 a batch of RSUs/PSUs vested and were converted into shares; 106,093 of those vested shares were surrendered/withheld to satisfy tax withholding, producing $449,834. On Feb 3, 2026 he exercised options for 300,000 shares at an exercise price of $1.24, paying $372,000 in cash.
The filing also shows additional administrative derivative conversion entries (zero‑price entries) related to RSU/PSU settlement and a one‑share rounding correction noted in the footnotes.

Key Details

Transaction dates/prices:
- Jan 31, 2026: RSUs/PSUs vested and converted to shares (footnotes F1–F4). 272,983 shares reported as issued from derivative conversion; 106,093 shares were surrendered/withheld to cover taxes (disposed) for $449,834.
- Feb 3, 2026: Exercise of options for 300,000 shares at $1.24 per share; cash paid = $372,000. (Option fully vested per F5.)
Shares owned after transaction: not specified in the provided filing details.
Footnotes:
- F1–F4: RSUs represent contingent rights to shares; original RSU grant vested in three equal annual installments and was fully vested as of Jan 31, 2026; performance criteria for certain PSUs were satisfied; one‑share rounding correction.
- F5: The option exercised is fully vested and exercisable.
Filing/timeliness: Form 4 was filed Feb 3, 2026 (reporting activity dated Jan 31 and Feb 3). No late filing flag is shown in the provided data.

Context

The Jan 31 entries reflect compensation vesting (RSUs/PSUs); the 106,093 surrendered shares represent tax withholding, a routine administrative transaction that reduces the net shares received from vesting. The Feb 3 option exercise was a cash exercise (he paid $1.24 per share) rather than an immediate open‑market sale; aside from shares withheld for taxes, there is no indication in this filing that the exercised shares were sold on the open market.
Purchases/exercises (paying cash to acquire shares) can be interpreted by some investors as a vote of confidence, but vesting and withholding transactions are often routine compensation events.

Form 4

Period: 2026-01-31

DirectorPresident, CEO, and Chairman

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-31+272,983→ 573,923 total
Tax Payment
Common Stock
2026-01-31$4.24/sh−106,093$449,834→ 467,830 total
Exercise/Conversion
Common Stock
2026-02-03$1.24/sh+300,000$372,000→ 767,830 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-01-31−173,466→ 0 total
→ Common Stock (173,466 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4][F3]
2026-01-31−99,517→ 0 total
→ Common Stock (99,517 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F5]
2026-02-03−300,000→ 0 total
Exercise: $1.24Exp: 2026-12-08→ Common Stock (300,000 underlying)

Holdings

Footnotes (5)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
[F3]Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
[F4]Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026.
[F5]The option is fully vested and exercisable.

Signature

/s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi|2026-02-03

1 file